Daré Bioscience (NASDAQ:DARE) Downgraded to Hold at Brookline Capital Management

Daré Bioscience (NASDAQ:DARE) was downgraded by Brookline Capital Management from a “buy” rating to a “hold” rating in a note issued to investors on Wednesday, Marketbeat reports.

A number of other equities analysts also recently commented on the stock. Dawson James downgraded shares of Daré Bioscience from a “buy” rating to a “neutral” rating in a research note on Tuesday, January 30th. HC Wainwright restated a “buy” rating and set a $6.00 price objective on shares of Daré Bioscience in a research note on Monday, April 1st.

Daré Bioscience Trading Up 4.4 %

Shares of NASDAQ DARE opened at $0.30 on Wednesday. The firm has a market cap of $29.68 million, a PE ratio of -0.87 and a beta of 1.16. Daré Bioscience has a 1-year low of $0.27 and a 1-year high of $1.10. The company has a fifty day moving average price of $0.46 and a 200 day moving average price of $0.40.

Hedge Funds Weigh In On Daré Bioscience

Large investors have recently modified their holdings of the business. Bank of New York Mellon Corp bought a new stake in shares of Daré Bioscience in the 1st quarter valued at about $34,000. Citigroup Inc. bought a new stake in shares of Daré Bioscience in the 1st quarter valued at about $40,000. Bank of America Corp DE bought a new stake in shares of Daré Bioscience in the 1st quarter valued at about $44,000. Morgan Stanley raised its holdings in shares of Daré Bioscience by 283.4% in the 4th quarter. Morgan Stanley now owns 67,646 shares of the biotechnology company’s stock valued at $56,000 after purchasing an additional 50,000 shares during the period. Finally, UBS Group AG raised its holdings in shares of Daré Bioscience by 11,198.4% in the 3rd quarter. UBS Group AG now owns 56,492 shares of the biotechnology company’s stock valued at $57,000 after purchasing an additional 55,992 shares during the period. 6.70% of the stock is currently owned by institutional investors and hedge funds.

Daré Bioscience Company Profile

Daré Bioscience, Inc, a clinical-stage biopharmaceutical company, engages in the identifying, developing, and marketing products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health.